Protein Kinase Inhibitors: all 15,278 studies that test it

Page 44 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With OsteosarcomaCompletedNCT02432274Phase 1/2Results posted
• Impact of Everolimus on HIV Persistence Post Kidney or Liver TransplantCompletedNCT02429869Phase 4Results posted
• Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic CholangiocarcinomaCompletedNCT02428855Phase 2Results posted
• Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K ActivationCompletedNCT02428296Phase 2Results posted
• Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT02427451Phase 1/2Results posted
• Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264CompletedNCT02424799Phase 1Results posted
• A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung CancerCompletedNCT02424617Phase 1/2Results posted
• A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular CarcinomaCompletedNCT02423343Phase 1/2Results posted
• Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild ADCompletedNCT02423200Phase 2Results posted
• A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)CompletedNCT02423122Phase 2Results posted
• Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.CompletedNCT02422615Phase 3Results posted
• A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationCompletedNCT02421939Phase 3Results posted
• Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationCompletedNCT02420912Phase 2Results posted
• Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic LeukemiaTerminatedNCT02420717Phase 2Results posted
• Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut OriginCompletedNCT02420691Phase 2Results posted
• A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras MutationsTerminatedNCT02418000Phase 1/2Results posted
• Sapanisertib in Treating Patients With Stage IV or Recurrent Lung CancerCompletedNCT02417701Phase 2Results posted
• Ibrutinib in Treating Patients With Advanced Systemic MastocytosisTerminatedNCT02415608Phase 2Results posted
• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)CompletedNCT02414139Phase 2Results posted
• A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02411591Phase 1Results posted
• A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingNCT02411448Phase 3Results posted
• Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)TerminatedNCT02410551Phase 2Results posted
• A Study of Enzalutamide and LY3023414 in Men With Prostate CancerCompletedNCT02407054Phase 2Results posted
• Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT02404220Phase 1/2Results posted
• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid TumorsCompletedNCT02403271Phase 1/2Results posted
• A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic TumoursCompletedNCT02402062Phase 2Results posted
• A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal CancerTerminatedNCT02402036Phase 2Results posted
• CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid TumorsCompletedNCT02401815Phase 1/2Results posted
• An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamideCompletedNCT02400476Phase 2Results posted
• A Pilot Study of Ruxolitinib in Secondary Hemophagocytic SyndromeCompletedNCT02400463Phase 2Results posted
• Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia PatientsCompletedNCT02400255Phase 2Results posted
• Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02399215Phase 2Results posted
• Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal CancerCompletedNCT02393755Phase 1/2Results posted
• Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid CancerCompletedNCT02393690Phase 2Results posted
• Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)TerminatedNCT02393248Phase 1/2Results posted
• Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02393209Phase 1/2Results posted
• Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT02391116Phase 2Results posted
• Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)TerminatedNCT02389764Phase 2Results posted
• A Study of Abemaciclib in Participants With Varying Degrees of Liver ImpairmentCompletedNCT02387814Phase 1Results posted
• ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background MethotrexateCompletedNCT02387762Phase 2Results posted
• A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast CancerCompletedNCT02384239Phase 2Results posted
• Regorafenib Plus Gemcitabine in Metastatic Pancreatic CancerTerminatedNCT02383433Phase 2Results posted
• A Rollover Protocol of Dacomitinib For Patients In JapanCompletedNCT02382796Phase 2Results posted
• BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast CancerCompletedNCT02379247Phase 1/2Results posted
• Trial of Afatinib in Pediatric TumoursCompletedNCT02372006Phase 1/2Results posted
• Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)CompletedNCT02371369Phase 3Results posted
• Afatinib in NSCLC With HER2 MutationCompletedNCT02369484Phase 2Results posted
• Phase III Copanlisib in Rituximab-refractory iNHLCompletedNCT02369016Phase 3Results posted
• Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal CancerCompletedNCT02368886Phase 2Results posted
• Dabrafenib and Trametinib in Treating Patients With BRAF Mutated AmeloblastomaCompletedNCT02367859Phase 2Results posted
• Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid TumorsTerminatedNCT02367352Phase 1Results posted
• Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)CompletedNCT02367040Phase 3Results posted
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF TherapyCompletedNCT02365649Phase 2Results posted
• An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerActive, not recruitingNCT02365597Phase 2Results posted
• ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic CancerCompletedNCT02362048Phase 2Results posted
• ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2Results posted
• Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone SarcomasCompletedNCT02357810Phase 2Results posted
• Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMDCompletedNCT02357342Phase 2Results posted
• LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular DegenerationCompletedNCT02355028Phase 2Results posted
• Vemurafenib and TIL Therapy for Metastatic MelanomaCompletedNCT02354690Phase 1/2Results posted
• Stem Cell Monitoring for CML Patients Undergoing Nilotinib TherapyCompletedNCT02353728Phase 2Results posted
• Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 MutationsCompletedNCT02352844Phase 2Results posted
• Study of Ibrutinib in Subjects With Acute Myeloid LeukemiaTerminatedNCT02351037Phase 2Results posted
• Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)TerminatedNCT02349633Phase 1/2Results posted
• Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerActive, not recruitingNCT02345265Phase 2Results posted
• Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)TerminatedNCT02343939Phase 1/2Results posted
• Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid MalignanciesCompletedNCT02343120Phase 1/2Results posted
• Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid TumoursCompletedNCT02341456Phase 1Results posted
• Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic LeukemiaCompletedNCT02340780Phase 2Results posted
• A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor TherapyTerminatedNCT02340221Phase 3Results posted
• A Study to Measure Baricitinib (LY3009104) Absorption in Healthy ParticipantsCompletedNCT02340104Phase 1Results posted
• Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With EverolimusCompletedNCT02338609Phase 4Results posted
• Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLCompletedNCT02337829Phase 2Results posted
• Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLCCompletedNCT02337530Phase 2Results posted
• A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to LeptomeningesCompletedNCT02336451Phase 2Results posted
• Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.TerminatedNCT02335944Phase 1/2Results posted
• A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of PalbociclibCompletedNCT02334800Phase 1Results posted
• Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line ChemotherapyTerminatedNCT02334527Phase 2Results posted
• Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT02332980Phase 2Results posted
• Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232TCompletedNCT02332902Phase 2Results posted
• Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)CompletedNCT02329860Phase 3Results posted
• A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic MalignanciesCompletedNCT02329847Phase 1/2Results posted
• Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell MalignanciesCompletedNCT02328014Phase 1/2Results posted
• A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic MalignanciesCompletedNCT02327169Phase 1Results posted
• A Study of LY2835219 in Healthy ParticipantsCompletedNCT02327143Phase 1Results posted
• FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB ExpressionCompletedNCT02325739Phase 1/2Results posted
• Pilot Efficacy and Safety Study of AQX-1125 in Atopic DermatitisCompletedNCT02324972Phase 2Results posted
• Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung CancerTerminatedNCT02323126Phase 2Results posted
• Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)TerminatedNCT02323113Phase 1/2Results posted
• A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has SpreadTerminatedNCT02322814Phase 2Results posted
• A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male VolunteersCompletedNCT02322749Phase 1Results posted
• TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet ChemotherapyTerminatedNCT02322281Phase 3Results posted
• Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis PatientsCompletedNCT02321930Phase 4Results posted
• A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung CancerCompletedNCT02321540Phase 1/2Results posted
• Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line TherapyCompletedNCT02317627Phase 2Results posted
• Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung CancerCompletedNCT02317016Phase 1Results posted
• Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive SurgeryTerminatedNCT02315625Phase 2Results posted
• Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02315430Phase 2Results posted
• Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or TrametinibTerminatedNCT02314143Phase 2Results posted
• Tofacitinib for the Treatment of Alopecia Areata and Its VariantsCompletedNCT02312882Not applicableResults posted

← Protein Kinase Inhibitors overview